MalarVx, Inc., a clinical-stage vaccine company, is proud to announce a license to HDT Bio's proprietary self-amplifying replicon RNA (repRNA) and lipid nanoparticle (LIONtm) technologies for use in ...
MalarVx, Inc., a clinical-stage vaccine company, is proud to announce a license to HDT Bio's proprietary self-amplifying ...
CES 2025 showcased advances in power and size savings, from energy-harvesting solutions to tiny sensors for wearables.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback